Oncolytics Biotech : Dose Escalation in Combination REOLYSIN®/Paclitaxel and Carboplatin Trial

4/14/2008 - April 14, 2008 - Oncolytics Biotech Inc. (“Oncolytics”) (TSX:ONC, NASDAQ:ONCY) has completed patient enrolment in the dose escalation portion of its U.K. clinical trial to evaluate the anti-tumour effects of systemic administration of REOLYSIN® in combination with paclitaxel and carboplatin in patients with advanced cancers including head and neck, melanoma, lung and ovarian... Oncolytics Biotech's Press Release -